Nautilus Biotechnology NAUT
NASDAQ NAUT
$0.95 +0.05 (+5.79%)
At close: Aug 21, 2026 · 4:00 PM EDT

Nautilus Biotechnology (NAUT) Income from Continuing Operations (2020 - 2026)

Nautilus Biotechnology (NAUT) posted Income from Continuing Operations of 50546000.0 for Q2 2026, up 4.44% sequentially from 52895000.0 in Q2 2025, and up 4.44% YoY from 48396761.1 in Q2 2025.

Nautilus Biotechnology (NAUT) Income from Continuing Operations (2020 - 2026) Analysis & Trends

Nautilus Biotechnology has reported Income from Continuing Operations for 4 years, with the latest figure at 50546000.0 in Q2 2026.

  • Quarterly Income from Continuing Operations rose 4.44% year-over-year to 50546000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 106897028.0 (down 87.74% YoY) and the FY2020 annual result came in at 41276035.0, changed N/A from the prior year.
  • Income from Continuing Operations advanced to 50546000.0 in Q2 2026 per NAUT's latest filing, from 52895000.0 in the prior quarter.
  • Over five years, Income from Continuing Operations peaked at 50546000.0 in Q2 2026 and troughed at 52895000.0 in Q2 2025.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn 1.10 Bn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn 1.30 Bn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn 482.00 Mn
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn -782.00 Mn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn 237.01 Mn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn 164.49 Mn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn -174.37 Mn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn -13.27 Mn
9 Royalty Pharma 27.27 Bn 26.43 Bn - 81.49 Mn
10 Nautilus Biotechnology 120.16 Mn 120.16 Mn 175,000.00 -14.46 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 -50.55 Mn
Jun 30, 2025 -52.90 Mn
Mar 31, 2021 -2.08 Mn
Dec 31, 2020 -1.38 Mn
Sep 30, 2020 -586,388.00